Long-term tolerability of nasal spray formulation of salmon calcitonin

Abstract One hundred postmenopausal women with osteoporosis treated with nasal spray calcitonin were followed up in three centers for 15 months. The therapeutic regimen consisted of four cycles of continuous treatment, each followed by a one-month drug-free interval. At any study visit, no more than three patients showed abnormal finding at rhinoscopy. Only four patients did not complete the study due to adverse events, all of moderate intensity. As far as the analgesic effect of study drug is concerned, for all variables, a statistically significant improvement ( P